Leukotriene Antagonists

Selectively inhibit the cysteinyl leukotriene receptor, increased activity of which is involved in airway oedema and bronchial smooth muscle constriction.

Property Montelukast
Class Leukotriene Antagonist
Uses Asthma, allergic rhinitis
Route of Administration PO
Dosing 10mg daily
Absorption 64% PO bioavailability
Distribution t0.5 5 hours, >99% protein bound
Metabolism Hepatic by CYP3A4
Elimination Predominantly faecal
Resp Bronchodilatation

References

  1. . Lexicomp. Montelukast: Drug information. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2017.
Last updated 2017-09-20

results matching ""

    No results matching ""